talkbio – Page 22

FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population

2 months ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), Health conditions:-:Point in time:^Patient:-, Novavax, Nuvaxovid, protein-based vaccine, restricted population, United States Food and Drug Administration, Vaccines

Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions

Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million

2 months ago talkbio0Tagged Acquisition, Bankruptcy, data privacy, Genetic testing for cancer risk, Genome, personal genome service, Purchased Services, Clinical and Biomedical, Research, Regeneron, total health

Regeneron; 23andMe; acquisition; bankruptcy; genetic testing; genome; personal genome service; total health; research services; data privacy

Pfizer-backed CellCentric Secures $120M for Myeloma Drug Trials

2 months ago talkbio0Tagged Accelerated, Approved, CellCentric, Clinical Trials, Inobrodib, Multiple Myeloma, oral drug, p300/CBP inhibitor, Pfizer, Series C

CellCentric; Pfizer; multiple myeloma; Series C funding; inobrodib; p300/CBP inhibitor; oral drug; clinical trials; phase 2/3; accelerated approval

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

2 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Applied Therapeutics’ Rare Disease Drug Fails Another Phase 3 Trial After FDA Rejection

2 months ago talkbio0Tagged Aldose Reductase Inhibitor, Apply, Cautionary Warning, Classical galactosemia, clinical trial conduct, Govorestat, Infrequent, Rejection, United States Food and Drug Administration

Applied Therapeutics; govorestat; rare disease; phase 3 failure; FDA rejection; classic galactosemia; aldose reductase inhibitor; clinical trial conduct; FDA warning letter

Recent Developments in Building Robust Health System Partnerships for Life Sciences (2025)

2 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Biotechnology, Computer Security, Data Integration, digital transformation, health system partnerships, Primary Health Care, Salesforce Life Sciences Cloud, strategic partnerships

health system partnerships; life sciences; strategic partnerships; digital transformation; artificial intelligence; cybersecurity; primary care; biotechnology; Salesforce Life Sciences Cloud; data integration

ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty

2 months ago talkbio0Tagged ASCO25, Cancer Research, Changing, Diagnostics, expert, Immunotherapy, Neoplasms, perspectives, Policy, Precision Medicine, regulatory uncertainty

ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes

Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

2 months ago talkbio0Tagged Appointments, biotech, CEO, Challenge, departure - ActRelationshipType, Eli Lilly competition, Flagship, Lars Fruergaard Jørgensen, Market, Nordisk, Obesity, Scholar Rock

Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock